Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) is co-investing in Warp Drive Bio, an innovative start-up biotechnology company, along with 2 venture capital firms, Third Rock Ventures (TRV), a venture capital firm based in Boston, Massachusetts, and Greylock Partners, a venture capital firm based in Menlo Park, California. Warp Drive Bio is an innovative biotechnology company, focusing on proprietary genomic technology to discover drugs of natural origin.

Warp Drive Bio proprietary technology was conceived by world leading scientist Gregory Verdine, Ph.D., and incubated at Third Rock Ventures for two years. Joining Dr. Verdine as co-founders are George Church, Ph.D. and Jim Wells, Ph.D. The Warp Drive Bio team has been assembling an array of technologies to create a platform for identifying potential drug candidates using microbiology, next generation sequencing, cutting-edge bioinformatics and chemo-informatics. Warp Drive Bio's integrated process pairs a 'genomic search engine' and customized search queries that enable natural products that are hidden within micro-organisms to be identified on the basis of their distinctive genomic signature.

Under the terms of the agreement, Sanofi and TRV / Greylock will invest in Warp Drive Bio at parity. Total program funding over the first 5 years could amount to up to $125 million, including an equity investment of up to $75 million.

Sanofi will give Warp Drive Bio access to its strains library and natural product expertise and will be granted certain access rights to Warp Drive Bio's technology and products, on a worldwide basis.

Warp Drive Bio remains an independent company and retains strategic direction, operational management and the right to develop and commercialize assets. This agreement enables Warp Drive Bio to advance its core research and development plan to proof of concept in collaboration with Sanofi, while also maintaining the ability to secure additional partnerships.

"We are very excited about this investment and collaborative partnership in a start-up biotechnology company based on outstanding science" declared Elias Zerhouni, President, Global Research & Development, Sanofi. "By combining Warp Drive Bio's unique proprietary technology and Sanofi's extensive drug development capabilities, we are convinced that this open and creative model of pharma-biotech partnership will boost innovation for the benefit of patients."

"This innovative collaboration between Sanofi and Third Rock Ventures provides the opportunity to build significant value and the potential for venture capital levels of return," said Alexis Borisy, partner at Third Rock Ventures and interim Chief Executive Officer of Warp Drive Bio. "Importantly, it also enables us to advance and accelerate the development of our proprietary genomics platform, unlock 'nature's drugs' and, ultimately, create breakthrough therapies for patients."

"Revolutionary advances in microbial genomics have provided the blueprints for nature's factories that assemble natural products, and have revealed vast treasure troves of novel natural product drugs hidden within microbes," said Gregory L. Verdine, Ph.D., Harvard University chemical biologist, venture partner at Third Rock Ventures and co-founder of Warp Drive Bio. "Prior to Warp Drive Bio, no one had created a comprehensive discovery engine that selectively mines from nature those products with transformative pharmaceutical potential. Warp Drive Bio has developed that capability and is using it to discover powerful next-generation drugs that target the central circuitry of human cells in completely new ways. We are thrilled to be working closely with Sanofi and our other partners as we aggressively move forward to bring these desperately needed medications to patients suffering from life-threatening and debilitating diseases."

About Warp Drive Bio
Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world's most powerful medicinal chemist, Warp Drive is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within micro-organisms. Key to the Warp Drive approach is the company's proprietary 'genomic search engine' and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signature.

About Third Rock Ventures
Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $800 million and two funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients. The firm has assembled a team with deep expertise and a proven track record of building respected and successful life sciences companies. With decades of complementary, cross-functional operational and leadership experience, the Third Rock team actively engages with its portfolio companies to provide hands-on strategy and experience to successfully launch companies with the best vision, science, operations, people and culture. With offices in Boston, MA and San Francisco, CA, Third Rock is well positioned geographically to closely collaborate with its portfolio companies to achieve their goals.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]